Omid Shafaat

Omid Shafaat

Auto-generated profile, based on publicly available information

Omid Shafaat

Division of Vascular and Interventional Radiology, Department of Radiology, Columbia University Irving Medical Center, NewYork-Presbyterian Hospital, 622 W 168th St, PH Room 1-301, New York, NY 10032

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in European Journal of Radiology Open
Verified
Journal Article
Open access
HSHouman Sotoudeh
Houman Sotoudeh
OSOmid Shafaat
Omid Shafaat
NANoha Aboueldahab
Noha Aboueldahab
MVMichael Vaphiades
Michael Vaphiades
ESEhsan Sotoudeh
Ehsan Sotoudeh
JBJoshua Bernstock
Joshua Bernstock
Superior ophthalmic vein thrombosis (SOVT) is an extremely rare condition. Few studies have been published about clinical aspects of this condition. In this study, we have studied the symptoms, underlying etiologies, treatment, pathogenesis and complication of the SOVT and we tried to classify it based on the etiology, treatment, and prognosis. We reviewed the patients' data from a tertiary academic referral center. Each patient with SOVT was then reviewed for symptoms associated with SOVT, underlying etiology, treatment protocol, treatment response, complications, possible pathogens, and final outcome. Twenty-four cases of SOVT were included in this study. Overall, 13 cases were diagnosed as right-sided SOVT, out of which, eight had simultaneous right-sided cavernous sinus thrombosis (CST). Eighteen cases were diagnosed to have left-sided SOVT, out of which, 11 had simultaneous left-sided CST. The SOVT can be secondary to different mechanisms. The SOVT secondary to trauma, recent surgery and coagulopathy are mostly non-aggressive, and can be managed by conservative therapy and anticoagulation. The SOVT in patients with orbital cellulitis, history of active sinusitis or paranasal sinus surgery are aggressive presenting with acute orbital swelling, abscess and visual loss. This type of SOVT can be complicated by extension to the cavernous sinus and intracranial structures. These patients require urgent antibiotics therapy and sinus surgery. The most severe type of SOVT is caused by mucormycosis which may also extend intracranially resulting in stroke and is often life-threatening.

1 October 2021 in Neuroradiology
Verified
Journal Article
Closed access
PDF file
SGSiddhartha Gaddamanugu
Siddhartha Gaddamanugu
OSOmid Shafaat
Omid Shafaat
HSHouman Sotoudeh
Houman Sotoudeh
ASAmir Hossein Sarrami
Amir Hossein Sarrami
ARAli Rezaei
Ali Rezaei
ASAparna Singhal
Aparna Singhal

1 June 2022 in Journal Of Neuroradiology
Verified
Journal Article
Closed access
OSOmid Shafaat
Omid Shafaat
JBJoshua Bernstock
Joshua Bernstock
ASAmir Shafaat
Amir Shafaat
VYVivek Yedavalli
Vivek Yedavalli
GEGalal Elsayed
Galal Elsayed
HSHouman Sotoudeh
Houman Sotoudeh

8 January 2022 in American Journal of Transplantation
Verified
Journal Article
Open access
XCXiaomeng Chen
Xiaomeng Chen
OSOmid Shafaat
Omid Shafaat
YLYi Liu
Yi Liu
EKElizabeth A. King
Elizabeth A. King
CWClifford Raabe Weiss
Clifford Raabe Weiss
MMMara A. McAdams-DeMarco
Mara A. McAdams-DeMarco
Kidney transplantation (KT) experts did not support the use of subjective unintentional weight loss to measure shrinking in the Physical Frailty Phenotype (PFP); a clinically feasible and predictive measure of shrinking is needed. To test whether unintentional weight loss could be replaced by an assessment of sarcopenia using existing CT scans, we performed a prospective cohort study of adult KT recipients with original PFP (oPFP) measured at admission (12/2008–2/2020). We ascertained sarcopenia by calculating skeletal muscle index from available, clinically obtained CTs within 1-year pre-KT (male<50cm2/m2; female<39cm2/m2) and combined it with the original 4 components to determine new PFP (nPFP) scores. Frailty was classified by frailty score: 0:non-frail;1–2:pre-frail;≥3:frail. Mortality and graft loss hazard ratios (HRs) were estimated using adjusted Cox proportional hazard models. Model discrimination was quantified using Harrell’s C-statistic. Among 1,113 recipients, 18.6% and 17.1% were frail by oPFP and nPFP, respectively. Compared to non-frail recipients, frail patients by either PFP had higher risks of mortality (oPFP HR=1.67,95%CI:1.07–2.62,C=0.710; nPFP HR=1.68,95%CI:1.06–2.66,C=0.710) and graft loss (oPFP HR=1.67,95%CI:1.17–2.40,C=0.631; nPFP HR=1.66,95%CI:1.15–2.40,C=0.634) with similar discriminations. oPFP and nPFP are equally useful in risk prediction for KT recipients; oPFP may aid in screening patients for pre-KT interventions, while nPFP may assist in nuanced clinical decision-making.

1 December 2021 in Cureus
Verified
Journal Article
Open access
HSHouman Sotoudeh
Houman Sotoudeh
ASAmir Hossein Sarrami
Amir Hossein Sarrami
GRGlenn H. Roberson
Glenn H. Roberson
OSOmid Shafaat
Omid Shafaat
ZSZahra Sadaatpour
Zahra Sadaatpour
MTMANOJ TANWAR
MANOJ TANWAR
Radiomics has achieved significant momentum in radiology research and can reveal image information invisible to radiologists’ eyes. Radiomics first evolved for oncologic imaging. Oncologic applications (histopathology, tumor grading, gene mutation analysis, patient survival, and treatment response prediction) of radiomics are widespread. However, it is not limited to oncologic analysis, and any digital medical images can benefit from radiomics analysis. This article reviews the current literature on radiomics in non-oncologic, neurological disorders including ischemic strokes, hemorrhagic stroke, cerebral aneurysms, and demyelinating disorders.

1 January 2015 in Tuberculosis Research and Treatment
Verified
Journal Article
Open access
PDF file
AFAliasghar Farazi
Aliasghar Farazi
OSOmid Shafaat
Omid Shafaat
MSMasoomeh Sofian
Masoomeh Sofian
MKManijeh Kahbazi
Manijeh Kahbazi
Background. Dietary supplementation has been used as a mechanism to augment the immune system. Adjunctive therapy with L-arginine has the potential to improve outcomes in active tuberculosis.Methods. In a randomized clinical trial 63 participants with smear-positive pulmonary tuberculosis in Markazi Province of Iran were given arginine or placebo for 4 weeks in addition to conventional chemotherapy. The final treatment success, sputum conversion, weight gain, and clinical symptoms after one and two months were considered as primary outcomes and secondary outcomes were ESR, CRP, and Hg. Data were collected and analyzed with SPSS software (ver. 18).Results. Arginine supplementation reduced constitutional symptoms (P=0.032) in patients with smear-positive TB at the end of the first month of treatment. Arginine treated patients had significantly increased BMI at the end of the first and second months of treatment (P=0.032andP=0.04) and a reduced CRP at the end of the first month of treatment (P=0.03) versus placebo group.Conclusion. Arginine is useful as an adjunctive therapy in patients with active tuberculosis, in which the effects are more likely mediated by the increased production of nitric oxide and improved constitutional symptoms and weight gain. This trial is registered with Clinical Trials Registry of Iran:IRCT201211179855N2.